Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 13/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272331 | 0.86 | JAK2 (0.57) | JAK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2255465 | 0.84 | NUDT1 (0.63) | JAK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18615147 | 0.84 | PSEN1 (0.53) | JAK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12518189 | 0.82 | JAK2 (0.57) | JAK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2253291 | 0.81 | TLR8 (0.39) | JAK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2634470 | 0.80 | JAK2 (0.70) | JAK2NUDT1 | |
| SCHEMBL18615054 | 0.79 | JAK2 (0.57) | JAK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2254342 | 0.79 | JAK2 (0.72) | JAK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12517030 | 0.78 | JAK2 (0.63) | JAK2NUDT1 | |
| SCHEMBL2268695 | 0.77 | NUDT1 (0.57) | JAK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111465603-B | Triazolopyridines as gamma secretase modulators | 勃林格殷格翰国际有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11339161-B2 | Triazolo pyridines as modulators of gamma-secretase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-24 | — | — | US | disclosed |
| EP-3672971-B1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BOEHRINGER INGELHEIM INT (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-20210017173-A1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-21 | — | — | US | disclosed |
| CN-111465603-A | Triazolopyridines as gamma-secretase modulators | 勃林格殷格翰国际有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-3672971-A1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | Boehringer Ingelheim International GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3347363-A1 | BRIDGED PIPERIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042114-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| US-9145399-B2 | Substituted bicyclic triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2454239-B1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2011086098-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011006903-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HPGDS, APP, PSEN1 | JAK2 2869/4885PSEN1 3/4885PSEN2 11/4885 |
| US-20210017173-A1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BACE1, BACE2, APP | JAK2 4676/4885PSEN1 4/4885PSEN2 5/4885 |
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | JAK2 2869/4885PSEN1 3/4885PSEN2 11/4885 |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | JAK2 4166/4885PSEN1 5/4885PSEN2 10/4885 |
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | JAK2 4105/4885PSEN1 5/4885PSEN2 10/4885 |
| US-11339161-B2 | Triazolo pyridines as modulators of gamma-secretase | BACE1, BACE2, APP | JAK2 4676/4885PSEN1 4/4885PSEN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.